Key result
Phosphodiesterase-4 inhibitors, specifically roflumilast, provide therapeutic efficacy for severe COPD not adequately controlled by bronchodilators, despite significant gastrointestinal side effects.
Roflumilast is an effective PDE4 inhibitor for severe COPD, though its use is limited by gastrointestinal side effects, with future potential in other inflammatory conditions.
No takes yet. Share an insight, caveat, or question.
May support roflumilast in uncontrolled severe COPD despite GI effects; leaves open comparative trials and non-COPD indications.
Beghé et al. (2013) conducted a review in Asthma and chronic obstructive pulmonary disease (COPD). Phosphodiesterase-4 (PDE4) inhibitors (e.g., roflumilast) was evaluated. Phosphodiesterase-4 inhibitors, specifically roflumilast, provide therapeutic efficacy for severe COPD not adequately controlled by bronchodilators, despite significant gastrointestinal side effects.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: